Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.
| Revenue (Most Recent Fiscal Year) | $0.50M |
| Net Income (Most Recent Fiscal Year) | $-4.95M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.15 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -138.71% |
| Return on Assets (Trailing 12 Months) | -62.76% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.37M |
| Free Float | 3.01M |
| Market Capitalization | $24.14M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | 4.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 52.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |